Terminated PHASE1 INTERVENTIONAL 3-arm NCT01110603

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors

Sponsor: Tesaro, Inc.

Conditions Cancer: Solid Tumors

Interventions MK-4827 carboplatin liposomal doxorubicin paclitaxel

Updated 6 times since 2017 Last updated: May 4, 2016 Started: Jul 31, 2010 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Tesaro, Inc.

More terminations from Tesaro, Inc.

This PHASE1 trial investigates Cancer: Solid Tumors and is currently terminated or withdrawn. Tesaro, Inc. leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tesaro, Inc.

Data source: Tesaro, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.